Related Experiment Video

Updated: Jun 18, 2025

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

20.4K

Management of Cardiovascular Diseases in Chronic Hemodialysis Patients

Zhen Zhang1,2,3,4, Yaqiong Wang1,2,3,4

  • 1Department of Nephrology, Zhongshan Hospital, Fudan University, 200032 Shanghai, China.

Reviews in Cardiovascular Medicine
|July 30, 2024
PubMed

Insights

Hemodialysis patients face high cardiovascular disease (CVD) risks, leading to significantly increased mortality. This review covers CVD characteristics in hemodialysis (HD) patients and explores recent management advancements.

Area of Science:

  • Nephrology
  • Cardiology
  • Internal Medicine

Background:

  • Hemodialysis (HD) is a primary treatment for end-stage kidney disease (ESKD).
  • Cardiovascular diseases (CVD) are a major cause of mortality in HD patients, with rates ~20 times higher than the general population.
  • Traditional and non-traditional risk factors worsen CVD progression and outcomes in HD patients.

Purpose of the Study:

  • To review the unique characteristics of cardiovascular diseases (CVD) in patients undergoing hemodialysis (HD).
  • To describe recent advancements in the management of CVD in the HD population.

Main Methods:

  • Literature review focusing on cardiovascular diseases in hemodialysis patients.
  • Synthesis of current understanding of CVD characteristics and risk factors.
  • Overview of contemporary management strategies and therapeutic advances.

Main Results:

  • HD patients exhibit a high prevalence and severity of cardiovascular diseases.
  • Accelerated CVD progression is linked to both traditional and non-traditional risk factors specific to the HD population.
  • Advances in management offer improved prognosis and quality of life.

Conclusions:

  • Effective management of CVD in HD patients requires addressing unique risk factors.
  • Ongoing research and clinical advancements are crucial for improving outcomes in this vulnerable population.
  • Integrated care approaches combining nephrology and cardiology are essential.

Keywords:
cardiovascular diseaseend-stage kidney diseasehemodialysis

More Related Videos

Assessment of Vascular Function in Patients With Chronic Kidney Disease08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.2K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

539

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
355
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
286
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.2K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.0K